BIA Separations selected to support AveXis’ gene therapy pipeline

BIA Separations, a leading biochromatography development and manufacturing company, today announced it is collaborating with AveXis, a Novartis company, to enhance the commercial purification process for its gene therapy pipeline, beginning with Zolgensma® (onasemnogene abeparvovec-xioi), the first U.S. Food and Drug Administration-approved gene therapy indicated for the treatment of pediatric patients with spinal muscular atrophy (SMA) who are less than two years of age.

BIA Separations selected to support AveXis’ gene therapy pipeline

Zolgensma is a one-time infusion that provides a functional copy of the human SMN gene to halt disease progression through sustained SMN protein expression.

BIA was selected as a result of its expertise in viral and DNA purification, particularly adeno-associated virus (AAV), and chromatographic technology for the purification and analysis of biomolecules.

Aleš Štrancar, CEO of BIA Separations commented:

We are proud to have been selected to support AveXis’ gene therapy pipeline. We look forward to seeing how Zolgensma helps the SMA community and the whole BIA team is honored to be a part of this important work.”

Andy Stober, Senior Vice President of Technical Operations for AveXis added:

We are especially grateful that BIA Separations shared, and operated, with the same sense of urgency we did to help bring gene therapy to the SMA community. BIA’s experience with AAV purification and its chromatographic technology were important contributions and we look forward to our continued work together.”

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    BIA Separations. (2019, July 22). BIA Separations selected to support AveXis’ gene therapy pipeline. News-Medical. Retrieved on October 18, 2019 from https://www.news-medical.net/news/20190722/BIA-Separations-selected-to-support-AveXise28099-gene-therapy-pipeline.aspx.

  • MLA

    BIA Separations. "BIA Separations selected to support AveXis’ gene therapy pipeline". News-Medical. 18 October 2019. <https://www.news-medical.net/news/20190722/BIA-Separations-selected-to-support-AveXise28099-gene-therapy-pipeline.aspx>.

  • Chicago

    BIA Separations. "BIA Separations selected to support AveXis’ gene therapy pipeline". News-Medical. https://www.news-medical.net/news/20190722/BIA-Separations-selected-to-support-AveXise28099-gene-therapy-pipeline.aspx. (accessed October 18, 2019).

  • Harvard

    BIA Separations. 2019. BIA Separations selected to support AveXis’ gene therapy pipeline. News-Medical, viewed 18 October 2019, https://www.news-medical.net/news/20190722/BIA-Separations-selected-to-support-AveXise28099-gene-therapy-pipeline.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post